RareCyte

Executive Summary

RareCyte, a Seattle-based private biotechnology company founded in 2016, specializes in advanced spatial biology and liquid biopsy platforms. Its core technologies—the Orion HT multiplex imaging system and the CyteFinder rare cell detection platform—enable high-plex, high-resolution analysis of tissues and circulating rare cells, supporting both research and diagnostic applications. The company also offers dedicated laboratory services. RareCyte's platforms are positioned to accelerate drug development and improve diagnostic accuracy, particularly in oncology and immuno-oncology, where spatial context and rare cell detection are critical. Despite being private with limited public financial data, the company's innovative technology has potential for significant impact. Key upcoming catalysts include potential FDA clearance for a diagnostic assay, a strategic pharmaceutical partnership to leverage its platforms in clinical trials, and the launch of a next-generation imaging system to expand its spatial biology capabilities.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of a liquid biopsy assay for early cancer detection40% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company for oncology clinical trials55% success
• Q1 2027Launch of next-generation Orion HT+ imaging system with expanded plex and resolution70% success